Aprea Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Aprea Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($2.97M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($3.24M) | Aug 12, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($3.24M) | Nov 12, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($3.93M) | Aug 12, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($3.93M) | Nov 12, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($3.93M) | May 14, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($3.78M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($3.47M) | Aug 12, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($3.47M) | Nov 12, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($2.81M) | May 14, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($2.81M) | Nov 12, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($2.81M) | Aug 12, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($3.20M) | Nov 7, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($3.26M) | Nov 7, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($3.26M) | Aug 12, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($4.38M) | Aug 12, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($4.38M) | May 14, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($4.38M) | Nov 7, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($4.02M) | Nov 9, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($98.26M) | Aug 10, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($3.12M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($3.39M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($4.09M) | May 14, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($4.10M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($3.85M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($3.15M) | May 14, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($3.52M) | Nov 7, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($3.65M) | Aug 12, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($4.62M) | May 14, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($4.20M) | Nov 9, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($98.47M) | Aug 10, 2023 |